TRPM8 agonist WS-3
Based on 1 Customer Validation
TRPM8 agonist WS-3 is an specific agonist of TRPM8 with an EC50 of 3.7 μM. TRPM8 agonist WS-3 inhibits epileptic seizures through a TRPM8 dependent mechanism. TRPM8 agonist WS-3 can be used for research on epilepsy and other conditions.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.35%
- CAS. Nr.: 39711-79-0
- Formel: C13H25NO
- Molecular Weight:211.35
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-75161
(-)-MentholEndogenous Metabolite -
HY-100208
HC-067047TRPV4 Antagonist -
HY-18779
PF-4840154TrpA1 Channel Agonist -
HY-11062
IcilinTRPM8 Agonist -
HY-108449
AcoltremonTRPM8 agonist -
HY-12245
SB-366791VR1/TRPV1 Antagonist -
HY-17568
NonivamideTRP Channel Agonist -
HY-108463
A-967079TRPA1 Receptor Antagonist -
HY-15064
HC-030031TRP Channel Inhibitor -
HY-19608
GSK1016790ATRPV4 Channel Agonist -
HY-12949
ML204TRPC4/TRPC5 Channel Inhibitor -
HY-101736
AMG9810TRPV1 Antagonist
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
Human Endogenous Metabolite |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Penicillin G induced male C57BL/6 mice (9-11 weeks, 24-30 g)[2]
-
Dosage:1 μM
-
Administration:cortical injection, single dose, administer 60 minutes after PG injection or 30 minutes before PG injection
-
Result:Significantly reduced glutamate levels.
Significantly reduced the power of epidermal discharges (ED).
Had no antiepileptic effect in TRPM8-KO mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 39711-79-0
-
Appearance Solid
-
Molecular Weight 211.35
-
Formel C13H25NO
-
Color White to off-white
-
SMILES
CC(C)C1CCC(C)CC1C(NCC)=O
-
Synonyms
Framidice 3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (473.15 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (554 KB)
- English - EN (554 KB)
- Français - FR (554 KB)
- Deutsch - DE (554 KB)
- Norwegian - NO (554 KB)
- Español - ES (554 KB)
- Swedish - SV (554 KB)
- Italian - IT (554 KB)
- Korean - KR (554 KB)
- Portuguese - PT (554 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Behrendt HJ, et al. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. [Content Brief]
[2]. Moriyama H, et al. Anti-seizure effects of WS-3, a TRPM8 agonist, on focal onset seizure mouse model via reduction of extracellular glutamate levels. Neuropsychopharmacology. 2025 Nov;50(12):1855-1863. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7315 mL | 23.6574 mL | 47.3149 mL | 118.2872 mL |
| 5 mM | 0.9463 mL | 4.7315 mL | 9.4630 mL | 23.6574 mL | |
| 10 mM | 0.4731 mL | 2.3657 mL | 4.7315 mL | 11.8287 mL | |
| 15 mM | 0.3154 mL | 1.5772 mL | 3.1543 mL | 7.8858 mL | |
| 20 mM | 0.2366 mL | 1.1829 mL | 2.3657 mL | 5.9144 mL | |
| 25 mM | 0.1893 mL | 0.9463 mL | 1.8926 mL | 4.7315 mL | |
| 30 mM | 0.1577 mL | 0.7886 mL | 1.5772 mL | 3.9429 mL | |
| 40 mM | 0.1183 mL | 0.5914 mL | 1.1829 mL | 2.9572 mL | |
| 50 mM | 0.0946 mL | 0.4731 mL | 0.9463 mL | 2.3657 mL | |
| 60 mM | 0.0789 mL | 0.3943 mL | 0.7886 mL | 1.9715 mL | |
| 80 mM | 0.0591 mL | 0.2957 mL | 0.5914 mL | 1.4786 mL | |
| 100 mM | 0.0473 mL | 0.2366 mL | 0.4731 mL | 1.1829 mL |
TRPM8 agonist WS-3 Related Classifications
HY-W014325 Related Classifications
Powered by Bioz